Chronic sinusitis and intravenous antibiotic therapy: Resolution, recurrence, and adverse events

Fowler, K.C.; Duncavage, J.A.; Murray, John; Tanner, S. Bobo

doi:10.1016/s0091-6749(03)80220-8

Cited by 12 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fowler et al reported a retrospective case series of 31 CRS patients who failed 3 courses of oral antibiotics and were subsequently treated with 4‐8 weeks of culture‐directed IV antibiotics 1126 . Only 29% of patients were noted to have resolution of disease on CT scan or nasal endoscopy following treatment.…”

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 99%

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

469

479

View full text Add to dashboard Cite

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.

show abstract

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 99%

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

469

479

View full text Add to dashboard Cite

show abstract

“…Fowler et al 772 performed a retrospective case series of 31 patients with CRS failing 3 courses of oral antibiotics and subsequently treated with an average of 4.8 weeks of culture-directed IV antibiotics. CRS was defined by continuous symptoms and positive findings on sinus CT scan and/or sinus endoscopy lasting for greater than 3 months.…”

Section: Viie4 Crssnp Management: Antibioticsmentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

Orlandi

Kingdom

Hwang

et al. 2016

Int Forum Allergy Rhinol

554

888

View full text Add to dashboard Cite

Background:The body of knowledge regarding rhinosinusitis (RS) continues to expand, with rapid growth in number of publications, yet substantial variability in the quality of those presentations. In an effort to both consolidate and critically appraise this information, rhinologic experts from around the world have produced the International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR:RS). Methods:Evidence-based reviews with recommendations (EBRRs) were developed for scores of topics, using previously reported methodology. Where existing evidence was insufficient for an EBRR, an evidence-based review (EBR) was produced. The sections were then synthesized and the entire manuscript was then reviewed by all authors for consensus. Results:The resulting ICAR:RS document addresses multiple topics in RS, including acute RS (ARS), chronic RS (CRS) with and without nasal polyps (CRSwNP and CRSsNP), recurrent acute RS (RARS), acute exacerbation of CRS (AE-CRS), and pediatric RS. Conclusion:As a critical review of the RS literature, ICAR:RS provides a thorough review of pathophysiology and evidence-based recommendations for medical and surgical treatment. It also demonstrates the significant gaps in our understanding of the pathophysiology and optimal management of RS. Too o en the foundation upon which these recommendations are based is comprised of lowerlevel evidence. It is our hope that this summary of the evidence in RS will point out where additional research efforts may be directed. C 2016 ARS-AAOA, LLC. Key Words:rhinosinusitis; chronic rhinosinusitis; acute rhinosinusitis; recurrent acute rhinosinusitis; evidence-based medicine; systematic review; endoscopic sinus surgery List of Abbreviations Used

show abstract

“…The success of this treatment has been reported in recent articles in the literature. [9][10][11][12] Although PICC lines have been shown to be safe and cost-effective, 13 they are not completely devoid of complications and, therefore, must be used judiciously in the treatment of chronic rhinosinusitis. Complications of outpatient parenteral antibiotic treatment (OPAT) include PICC line-specific complications such as thrombosis, phlebitis, catheter occlusion, catheter dislodgement, and catheter disruption.…”

mentioning

confidence: 99%